Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects
Authors:
- 1 December 2007
- journal article
- letter
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 7 (4) , 188-190
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetesCardiovascular Diabetology, 2007
- Endogenous Secretory Receptor for Advanced Glycation Endproducts Levels Are Correlated With Serum Pentosidine and CML in Patients With Type 1 DiabetesArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Positive association of serum levels of advanced glycation end products with thrombogenic markers in humansMetabolism, 2006
- Upregulation of RAGE and its ligands in proliferative retinal diseaseExperimental Eye Research, 2006
- Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertensionMicrovascular Research, 2005
- Diabetic Vascular Complications: Pathophysiology, Biochemical Basis and Potential Therapeutic StrategyCurrent Pharmaceutical Design, 2005
- Improved Arterial Compliance by a Novel Advanced Glycation End-Product Crosslink BreakerCirculation, 2001
- Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproductsNature Medicine, 1998
- Increased Levels of Soluble Adhesion Molecules in Type 2 (Non-Insulin Dependent) Diabetes mellitus Are Independent of Glycaemic ControlThrombosis and Haemostasis, 1994